Clinical Trial

Clearmind Medicine Achieved Positive Results in Cocaine Addiction Treatment

Tel Aviv, Israel / Vancouver, Canada, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY)…

10 months ago

NeoGenomics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Utility of RaDaR for Therapy Response

FT. MYERS, FL / ACCESSWIRE / December 5, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, today…

10 months ago

Biomea Fusion Announces Health Canada Clearance of Clinical Trial Application (CTA) for BMF-219 in Type 1 Diabetes

BMF-219 is a novel investigational covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes…

10 months ago

Checkpoint Therapeutics Strengthens Intellectual Property Protection for Cosibelimab with New U.S. Patent Issuance

Upcoming PDUFA goal date of January 3, 2024 U.S. patent protection for cosibelimab through at least May 2038 WALTHAM, Mass.,…

10 months ago

ANGLE launches Portrait+ CTC kit at SABCS

ANGLE LAUNCHES PORTRAIT+ CTC KIT AT SAN ANTONIO BREAST CANCER SYMPOSIUMANGLE's Portrait+ CTC staining kit combines the power of Parsortix®…

10 months ago

UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer

VIENNA, Va.--(BUSINESS WIRE)--$CVM #Multikine--CEL-SCI Corporation (NYSE American: CVM) today announced that the British National Institute for Health and Care Excellence…

10 months ago

UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer

VIENNA, Va.--(BUSINESS WIRE)--$CVM #Multikine--CEL-SCI Corporation (NYSE American: CVM) today announced that the British National Institute for Health and Care Excellence…

10 months ago

Gain Therapeutics to Participate in FORCE Family Office Event with Zacks Small-Cap Research

BETHESDA, Md., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (the “Company”), a biotechnology company leading the…

10 months ago

Stemtech Continues to Demonstrate Remarkable Growth and Innovation in 2023

Company Achieves NEW Rank Advancements, Acknowledges Sales Directors, and Sets Course for Future ExpansionNAPLES, FL / ACCESSWIRE / December 4,…

10 months ago